Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 29, 2008

ADVENTRX Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	**001-32157**	**84-1318182**
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

6725 Mesa Ridge Road, Suite 100
San Diego, CA 92121
(Address of Principal Executive Offices and Zip Code)

N/A
(Former name or former address if changed since last report)

Registrant's telephone number, including area code: **(858) 552-0866**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Table of Contents

Item 7.01. Regulation FD Disclosure.

Evan M. Levine, Chief Executive Officer and President of ADVENTRX Pharmaceuticals, Inc. ("ADVENTRX"), and other executive officers will present the information reflected in the slides attached as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") commencing April 29, 2008 at various investor and analyst meetings.

The information in this Report, including the slides attached hereto as Exhibit 99.1, is being furnished pursuant to this Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Report.

By filing this Report and furnishing this information, ADVENTRX makes no admission as to the materiality of any information in this Report. The information contained in the slides is summary information that is intended to be considered in the context of ADVENTRX's filings with the Securities and Exchange Commission (the "SEC") and other public announcements that ADVENTRX makes, by press release or otherwise, from time to time. ADVENTRX does not intend and undertakes no duty or obligation to publicly update or revise the information contained in this Report, although it may do so from time to time as its management believes is appropriate. Any such updating or revision may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

ADVENTRX cautions you that statements and information included in the slides attached hereto as Exhibit 99.1 that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; the risk that preclinical results are not indicative of the success of subsequent clinical trials and the results of pending clinical trials; the risk the FDA determines ADVENTRX's product candidates are not bioequivalent to the applicable reference product; difficulties or delays in developing, manufacturing, obtaining regulatory approval for and marketing ADVENTRX's product candidates; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; the scope and validity of patent protection for ADVENTRX's product candidates; patent and non-patent exclusivity covering Navelbine® and Taxotere®; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement included in the slides attached hereto as Exhibit 99.1 to reflect events or circumstances arising after the date on which it was made. This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934.

Table of Contents

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The list of exhibits called for by this Item is incorporated by reference to the Index to Exhibits filed with this report.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ADVENTRX Pharmaceuticals, Inc.

Dated: April 29, 2008

By: /s/ Patrick Keran
Name: Patrick Keran
Title: Vice President, Legal

INDEX TO EXHIBITS

99.1	Presentation Slides

EXHIBIT 99.1

Safe Harbor Statement

ADVENTRX cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; the risk that preclinical results are not indicative of the success of subsequent clinical trials and the results of pending clinical trials; the risk the FDA determines ADVENTRX's product candidates are not bioequivalent to the applicable reference product; difficulties or delays in developing, manufacturing, obtaining regulatory approval for and marketing ADVENTRX's product candidates; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; the scope and validity of patent protection for ADVENTRX's product candidates; patent and non-patent exclusivity covering Navelbine® and Taxotere®; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this presentation to reflect events or circumstances arising after the date on which it was made.

Corporate Overview

Two novel formulations of currently marketed chemotherapy drugs potentially on the market by 2010

Represent combined market opportunity in excess of $3 Billion

Clinical/regulatory strategy allows for shorter development timelines with decreased clinical risk and development cost

Third oncology product candidate, CoFactor®, addresses market opportunity in excess of $500 Million

Significant near term value drivers

Potential for revenues from drug sales in 2009

ADVENTRX Lead Product Candidates
2008 – 2010 Goals



Vinorelbine (Navelbine®)

- Vinorelbine is an injectable chemotherapeutic drug indicated as a single agent or in combination with cisplatin for first-line treatment of unresectable advanced NSCLC in the U.S. Approved in the E.U. for the treatment of NSCLC and advanced breast cancer

- Despite narrow label & generic pricing, worldwide sales in excess of $200 million
- Based on recent clinical data, we believe the market for vinorelbine-based treatments both in the U.S. & abroad will increase
- Vinorelbine has several limitations
  - Injection site reactions occur in one-third of patients
  - Reactions cause administration challenges for nurses and patients

ANX-530 (vinorelbine emulsion)

ANX-530 is designed to reduce the incidence and severity of injection site reactions

- **Registrational bioequivalence clinical study complete**
  - Primary endpoint met, pharmacokinetic equivalence observed between ANX-530 & Navelbine
  - In post-hoc analyses, ANX-530 showed a statistically significant reduction in injection site reactions (when compared to Navelbine)
- **NDA submission anticipated Q4 2008; potential market launch in 2009**
- **Market research indicates a preference for a formulation of vinorelbine that reduces or eliminates injection site reactions while providing comparable efficacy**
- **Premium pricing strategy could substantially increase existing market opportunity**

ANX-530 Registrational Clinical Study

Clinical Design:	Open Label, Crossover comparison of ANX-530 and Navelbine
Dosing Regimen:	Crossover study design, beginning with either a single dose of ANX-530 (30mg/m^2) administered via a 10 min. infusion in the first week, and a single dose of Navelbine (30mg/m^2) administered via a 10 min. infusion in the following week (or vice versa)
Primary Objective:	Demonstrating pharmacokinetic equivalence of ANX-530 and Navelbine
Secondary Objective:	Determining the safety of a single dose of ANX-530
Study Population:	31 patients with various advanced cancers
Clinical Sites:	7 (South America)

ANX-530 Registrational Clinical Study
Positive Results

Primary endpoint met in registrational bioequivalence clinical study of ANX-530

Statistically equivalent pharmacokinetics observed between ANX-530 and Navelbine



Hours	Plasma Vinorelbine (ng/mL)	
	ANX-530	Navelbine
0	8.52	27.9
0.17	221	212
0.33	105	107
0.67	71.2	71.8
1	51.4	58.3
3	28.5	31.6
6	18.6	15.6
24	6.26	5.42
48	3.05	2.97
72	1.84	1.78
144	0.79	0.746

ANX-530 Registrational Clinical Study
Positive Results

ANX-530 and Navelbine are considered to have equivalent pharmacokinetics if the upper and lower bounds of the AUC ratio's and the Cmax ratio's 90% confidence interval ranged from 80 to 125%



ANX-530 Preclinical Results
Lower Vein Irritation, Erythema & Edema



Vinorelbine: Due to the severity of toxicity, some of the animals could not receive either the second or third injections at certain doses, but were still analyzed for toxicity after each injection period.

*High dose Vinorelbine group received 1st injection only.

Low and medium dose Vinorelbine group could not receive the 3rd injection.



ANX-530

Vinorelbine

ANX-530 Preclinical Results
Ear Vein Histopathology

ANX-530 exhibited markedly less ear vein histopathological toxicity in preclinical studies

Cumulative Toxicity Score



Following intravenous treatment in rabbits, ear vein tissue sections were scored for severity of symptoms

- **(0 to 3 scale - no observable event to marked severity).**

Toxicity score represents the summation of scores from seven separate vein sections/rabbit.

ANX-530 Preclinical Results
Breast Tumor Xenograft

ANX-530 exhibits statistically equivalent antitumor activity compared to Navelbine in a mouse xenograft model



Similar results observed in a lung tumor model in mice

Day 28 Excised Tumors



Dose level = 8 mg/kg (24 mg/m² human equivalent dose), qdx6 intravenous treatment

n=12 (saline group); n=6/group (Navelbine & ANX-530 groups)

ANX-530 Preclinical Results
Pharmacokinetics

Pharmacokinetics statistically equivalent for ANX-530 in a rat pK model

Drug	$t_{1/2\alpha}$ (hr)	$t_{1/2\beta}$ (hr)	Vd (L/kg)	CL (L/hr/kg)	AUC_{0-24} (mg·hr/L)	$AUC_{0-\infty}$ (mg·hr/L)
ANX-530 (vinorelbine emulsion)	0.28	11.2	24.1	1.5	2271.5	2717.6
Vinorelbine solution (Navelbine)	0.28	11.7	25.7	1.5	2106.2	2892.0



Source: Cantwell, MJ, Robbins, JM, Chen, AX; A novel emulsion formulation of vinorelbine attenuates venous toxicity while maintaining antitumor efficacy; AACR 2006

n= 12/group

ANX-530 Key Milestones

2008

- ☑ Present PK Results from ANX-530 Registrational Bioequivalence Study at AACR
- Announce Safety Results from ANX-530 Registrational Bioequivalence Study at ASCO
- Submit and Plan to Present Safety Results from ANX-530 Registrational Bioequivalence Study Breast Cancer Patient Subset at the San Antonio Breast Cancer Symposium
- Submit U.S. New Drug Application (NDA)

2009

- FDA Acceptance of NDA for Filing
- Approval of NDA
- Market Launch

Docetaxel (Taxotere®)

- Taxotere is an injectable chemotherapeutic agent that is approved for the treatment of breast, non-small cell lung, prostate, head and neck & gastric cancers
- One of the top-selling anti-cancer agents in the world
- Taxotere sales in 2007 approx $2.9 billion
- Taxotere has several limitations
  - Formulated with polysorbate 80, a toxic detergent
  - Can cause acute hypersensitivity reactions
    - Patients must be pre-medicated to address these reactions; premedication with steroids has side effects
  - Administration and compatibility limitations
  - Stability limitations

ANX-514 (docetaxel emulsion)

ANX-514 is formulated without polysorbate 80 or other detergents and is designed to reduce the incidence and severity of hypersensitivity reactions

- **FDA affirmed 505(b)(2) clinical/regulatory path**
  - ***Patient enrollment in registrational bioequivalence clinical study of ANX-514 initiated***
- **Preclinical testing with ANX-514 indicated reduced hypersensitivity reactions without impact on pharmacokinetics or anti-tumor activity when compared to Taxotere**
- **Improved administration and compatibility with common supplies as well as improved stability**
- **Potential 2 year lead time over generic Taxotere**
  - **Docetaxel patent expires May 14, 2010**
  - **Taxotere patents expire July 3, 2012**
- **Market research indicates a preference for a docetaxel formulation that reduces hypersensitivity reactions**

ANX-514 Preclinical Results
Plasma Histamine Levels

Statistically lower hypersensitivity observed following ANX-514 administration compared to Taxotere in an animal model



Dose Level = 1 mg/kg. Duration of Infusion = 5 minutes.
Crossover Study Design. (n= 4 animals per group)
ADVENTRX data on file

ANX-514 Preclinical Results
Blood Pressure Changes

Systolic blood pressure drops following Taxotere treatment compared to ANX-514 in an animal model



Dose Level = 1 mg/kg. Duration of Infusion = 5 minutes.
Crossover Study Design. (n= 4 animals per group)
ADVENTRX data on file

ANX-514 Preclinical Results
Complement Activation

Taxotere induces statistically significant increase in serum complement activation compared to ANX-514



n = 10 normal human donor serum samples

ANX-514 Preclinical Results
Breast Tumor Xenograft

ANX-514 exhibits statistically equivalent antitumor activity compared to Taxotere in a mouse xenograft model



Similar results observed in liver and sarcoma tumor xenograft models in mice

Day 25 Excised Tumors



Dose level = 10 mg/kg (30 mg/m^2 human equivalent dose), q3dx4 intravenous treatment;
n=12 (saline group); n=6 (Taxotere & ANX-514 groups)

ANX-514 Preclinical Results
Pharmacokinetics

Pharmacokinetics statistically equivalent for ANX-514 in two separate animal models



	Taxotere	ANX-514
AUC	242	246
Cmax	183	157

n = 4 animals/group

	Taxotere	ANX-514
AUC	358	354
Cmax	374	739

n = 6 animals/group

ANX-514 Key Milestones

2008

- [x] Initiate Patient Enrollment in Registrational Bioequivalence Study
- [ ] Complete Patient Enrollment in Registrational Bioequivalence Study
- [ ] Announce PK Results from Registrational Bioequivalence Study

2009

- Submit and Plan to Present PK and Safety Results from Registrational Bioequivalence Study at Oncology Conferences
- Submit U.S. New Drug Application (NDA)
- FDA Acceptance of NDA for Filing

2010

- Approval of NDA
- Market Launch

Leucovorin/Isovorin®

- Leucovorin/Isovorin is a folate-based biomodulator that can be used to enhance the anti-cancer effect of 5-FU chemotherapy or to protect healthy cells from chemotherapy

- Indicated for use in metastatic colorectal and other cancers as well as in high dose methotrexate rescue
- Global market in excess of $500 million
- Leucovorin has several limitations
  - Requires multiple metabolic steps to become the active form of folate
  - Commonly administered as a 2 hour infusion

ANX-510 (CoFactor)

Folate-based biomodulator designed to replace leucovorin as the preferred method to enhance the activity and reduce the associated toxicity of the widely used cancer chemotherapeutic agent 5-FU

- **CoFactor directly delivers the active form of folate**
- **CoFactor can be administered within minutes as opposed to hours**
- **Two clinical trials & preclinical studies have demonstrated superior efficacy & reduced toxicity against historical comparison when 5-FU was administered as a bolus**

Results from three CoFactor clinical studies anticipated mid-2008

CoFactor Key Milestones

2008

- Announce Results Relating to the Primary Endpoint from CoFactor Phase 2 Breast Cancer study at ASCO
- Announce Results Relating to Overall Survival from CoFactor Phase 2b mCRC study
- Announce Available Results from CoFactor Phase 3 mCRC study
- Announce Results from CoFactor Pharmacokinetic Bridging Study
- Provide Update on CoFactor Program
- Submit and Plan to Present Results from the CoFactor Phase 2b & Phase 3 mCRC studies at the European Society for Medical Oncology Conference
- Submit and Plan to Present Results Relating to Progression Free Survival from the CoFactor Phase 2 Breast Cancer Study at the San Antonio Breast Cancer Symposium

ADVENTRX 2008 Milestones

- ☑ Present PK Results from ANX-530 Registrational Bioequivalence Study at AACR
- ☑ Initiate Patient Enrollment in ANX-514 Registrational Bioequivalence Study
- Announce Results Relating to the Primary Endpoint from CoFactor Phase 2 Breast Cancer study at ASCO
- Announce Safety Results from ANX-530 Registrational Bioequivalence Study at ASCO
- Announce Results Relating to Overall Survival from CoFactor Phase 2b mCRC study
- Announce Available Results from CoFactor Phase 3 mCRC study
- Announce Results from CoFactor Bridging Study
- Provide Update on CoFactor Program
- Complete Patient Enrollment in ANX-514 Registrational Bioequivalence Study
- Submit and Plan to Present Results from the CoFactor Phase 2b & Phase 3 mCRC studies at the European Society for Medical Oncology Conference
- Submit and Plan to Present Safety Results from ANX-530 Registrational Bioequivalence Study Breast Cancer Patient Subset at the San Antonio Breast Cancer Symposium
- Submit and Plan to Present Results Relating to Progression Free Survival from the CoFactor Phase 2 Breast Cancer Study at the San Antonio Breast Cancer Symposium
- Announce PK Results from ANX-514 Registrational Bioequivalence Study
- Submit U.S. NDA for ANX-530

ADVENTRX

PHARMACEUTICALS

Refining therapies for life